The aim should be to use the lowest dose possible Second-line treatment for OMA in adults that achieves the appropriate clinical outcome for following the use of corticosteroids. each patient. Induction Dose - 1–2 g/kg in 2 to 5 divided doses. Maintenance Dose - 0.4–1 g/kg, 4 to 6 weekly. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. Refer to the current product information sheet for further information. BIBLIOGRAPHY Glatz, K, Meinck, HM & Wildemann, B 2003, opsoclonus-myoclonus syndrome: high dose intravenous immunoglobulins are effective’, Journal of ‘Para-infectious Neurology, Neurosurgery and Psychiatry, vol. 74, no. 2, pp. 279–80. Kornberg, AJ, for the Asia–Pacific IVIg Advisory Board 2004, Bringing consensus to the use of IVIg in neurology. Expert consensus statements on the use of IVIg in neurology, 1st edn, Asia–Pacific IVIg Advisory Board, Melbourne, pp. 80–82. Kurtzke, JF 1983, neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)’, Neurology, vol. 33, no. 11, pp. 1444–1452. ‘Rating National Institute of Neurological Disorders 2006, opsoclonus myoclonus information page’, January. Available from: www.ninds.nih. ‘NINDS gov/disorders/opsoclonus_myoclonus/opsoclonus_myoclonus.htm [cited 7 Dec 2007]. END OF DOCUMENT
The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. Second-line treatment for OMA in adults following the use of corticosteroids. Induction Dose - 1–2 g/kg in 2 to 5 divided doses. Maintenance Dose - 0.4–1 g/kg, 4 to 6 weekly. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. Refer to the current product information sheet for further information. BIBLIOGRAPHY Glatz, K, Meinck, HM & Wildemann, B 2003, ‘Para-infectious opsoclonus-myoclonus syndrome: high dose intravenous immunoglobulins are effective’, Journal of Neurology, Neurosurgery and Psychiatry, vol. 74, no. 2, pp. 279–80. Kornberg, AJ, for the Asia–Pacific IVIg Advisory Board 2004, Bringing consensus to the use of IVIg in neurology. Expert consensus statements on the use of IVIg in neurology, 1st edn, Asia–Pacific IVIg Advisory Board, Melbourne, pp. 80–82. Kurtzke, JF 1983, ‘Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)’, Neurology, vol. 33, no. 11, pp. 1444–1452. National Institute of Neurological Disorders 2006, ‘NINDS opsoclonus myoclonus information page’, January. Available from: www.ninds.nih. gov/disorders/opsoclonus_myoclonus/opsoclonus_myoclonus.htm [cited 7 Dec 2007]. END OF DOCUMENT
opsoclonus-myoclonus-ataxia-oma.DOCX